RNAi Therapeutics Platform Targeting Cardiometabolic and Pulmonary Disease

Arrowhead Pharmaceuticals is a biopharmaceutical company that develops medicines using its proprietary Targeted RNAi Molecule (TRiM) platform. The platform enables tissue-specific delivery of RNA interference therapeutics, allowing the company to silence disease-causing genes in the liver, lung, muscle, and other tissues via subcutaneous or inhaled administration.

How It Makes Money:

• Product Revenue: Following the approval of plozasiran (ARO-APOC3) for FCS, the company generates commercial revenue, though at an early stage.
• Partnership and Licensing Revenue: Arrowhead has historically generated non-dilutive funding through collaborations (e.g., with GSK, Takeda, Amgen, and others), receiving upfront payments, milestone payments, and royalties.
• Grant and Other Revenue: Minor contributions from research grants.

Customers: The primary customers are patients, healthcare providers, and payers in the US and, pending approvals, international markets. Partnership revenue comes from large pharmaceutical collaborators.

Scale: With 140.86M shares outstanding and a public float of 122.45M, the company has a market cap of $10.6B. It remains pre-profitability with an EPS of $-2.28, reflecting heavy R&D investment. The company is headquartered in Pasadena, California, and employs several hundred people, with a focus on both discovery and clinical development.

Near-Term (12-24 Months):

• Plozasiran FCS Launch: Revenue ramp will depend on payer coverage and diagnosis rates. FCS is a rare disease, so peak sales in this indication alone may be modest ($100-300M), but the launch establishes commercial credibility.
• SHASTA-2 Data in sHTG: Phase 3 data readouts in severe hypertriglyceridemia could support a supplemental approval and significantly expand the addressable market.
• Lp(a) Program Advancement: Phase 2/3 data for ARO-LPA will be a major catalyst; positive results could drive partnership interest or accelerate internal development.
• Partnership Milestones: Existing collaborations may yield milestone payments that offset cash burn.

Medium-Term (3-5 Years):

• sHTG Approval and Launch: If approved, sHTG could drive the majority of plozasiran revenue, with peak sales estimates ranging from $1-3B depending on penetration and pricing.
• Lp(a) Commercialization: With no approved therapies, an Lp(a)-lowering RNAi could capture a multi-billion-dollar market, particularly if cardiovascular outcomes data demonstrate benefit.
• Pulmonary and Metabolic Programs: ARO-RAGE and ARO-INHBE represent earlier-stage optionality; positive data could open new therapeutic areas and attract partnerships.
• Platform Expansion: Additional tissue targets (CNS, muscle) could yield new INDs and further pipeline depth.

Note: Historical figures are illustrative approximations based on public filings and analyst estimates; actual results may differ. Revenue includes product and partnership revenue.

The financial trajectory shows a company investing heavily in R&D while beginning to scale commercial operations. Revenue growth is driven by the plozasiran launch and partnership milestones. Gross margins are expected to be high (typical for biologics) once product revenue scales. EPS remains negative but is projected to improve as revenue grows faster than operating expenses. The current EPS of $-2.28 (on a trailing basis) reflects the ongoing investment phase.

Market Size/TAM:

• FCS: Rare disease, ~3,000-5,000 patients in the US; global market potential ~$500M.
• sHTG: Affects ~3-5 million patients in the US; potential market >$5B.
• Lp(a): ~20% of global population; potential market >$10B if outcomes data support broad use.
• Pulmonary (Asthma/COPD): Large markets, but RNAi approach is early.

Competitive Positioning: Arrowhead's TRiM platform offers subcutaneous and inhaled delivery, enabling tissue-specific targeting. Key competitors include:

• Alnylam Pharmaceuticals (ALNY): Leader in RNAi with approved products (patisiran, givosiran, lumasiran, vutrisiran). Competes in ATTR amyloidosis and other liver targets.
• Ionis Pharmaceuticals (IONS): Antisense leader with pelacarsen (Lp(a)) in Phase 3 and olezarsen (APOC3) approved for FCS. Direct competitor to plozasiran.
• Novartis (NVS): Developing pelacarsen (licensed from Ionis) for Lp(a).
• Amgen (AMGN): Developing olpasiran (siRNA) for Lp(a), competitive threat.
• Regeneron (REGN): Has RNAi interests and broad pipeline.

Arrowhead's differentiation lies in its delivery technology and pipeline breadth, but it faces intense competition from larger, better-capitalized players.

DCF Discussion: A discounted cash flow analysis for Arrowhead is highly sensitive to assumptions on plozasiran sHTG approval, Lp(a) success, and pricing. Using a 10% discount rate and a 12% terminal growth rate, and assuming:

• Plozasiran peak sales of $2B by 2032 (FCS + sHTG)
• Lp(a) peak sales of $3B by 2033
• Operating margins reaching 35% at maturity
• Probability-weighted for clinical/regulatory risk

The DCF yields an equity value of approximately $9-12B, or $64-85 per share. At $76.59, the stock is trading within this range, suggesting the market is pricing in a base-case scenario.

Comparable Company Multiples:

Note: Multiples are illustrative and based on public market data approximations.

Arrowhead trades at a premium to Ionis on an EV/Revenue basis, reflecting its pipeline optionality but also execution risk. The premium is justified only if sHTG and Lp(a) programs succeed.

• Clinical and Regulatory Risk: Plozasiran's sHTG indication and the Lp(a) program are not yet approved. Failure in Phase 3 or regulatory rejection would materially impair value.
• Competitive Risk: Ionis's olezarsen is already approved for FCS and competes directly. Alnylam and Amgen are advancing Lp(a) therapies, potentially limiting market share.
• Commercial Execution Risk: Arrowhead has limited commercial experience. Payer reimbursement, diagnosis rates, and physician adoption for FCS and future indications are uncertain.
• Financing Risk: With negative EPS and high R&D spend, the company may need to raise capital, potentially diluting shareholders, especially if partnership milestones are delayed.
• Platform and Safety Risk: RNAi therapeutics carry risks of off-target effects or immune reactions. Any safety signal could halt development across the platform.